findmyKOL

Omar Alkharabsheh, MD

Basic profile

USA Mitchell Cancer Institute

ORCIDNPI
RegionCincinnati, OH · MidwestSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Omar Alkharabsheh is an Oncology physician affiliated with USA Mitchell Cancer Institute. OpenAlex indexes 71 publications with 314 citations (h-index 10).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
71publications

Distinct works indexed by OpenAlex, matched via ORCID.

314citations

Total citations across indexed works.

10h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
55companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

3151 Bellevue Ave
Cincinnati, OH 452192370

Telephone

513-475-8500

Provider last certified this registry record 20 May 2025.

View the NPPES registry record

Industry payments

55 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    45.8%
    Thalidomide Analog18.1%
    Lenalidomide49%Revlimid32%Pomalyst19%
    Part D<11 patients
    Kinase inhibitor17.5%
    Calquence35%Jakafi33%Imatinib Mesylate17%Imbruvica15%
    Part D<11 patients

    + 3 more classes in this area

  • Nervous system

    17.2%
    Gabapentinoids5.5%
    Gabapentin100%
    Part D<11 patients
    Opioid Agonist5.5%
    Oxycodone Hcl68%Oxycodone-Acetaminophen32%
    Part D<11 patients

    + 2 more classes in this area

  • Dermatology

    15%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15%
    Acyclovir100%
    Part D25 patients
Where care is delivered (Part B)14.8% facility · 85.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”